117 related articles for article (PubMed ID: 37767987)
1. Histomic and transcriptomic features of MRI-visible and invisible clinically significant prostate cancers are associated with prognosis.
Lehto TK; Pylväläinen J; Sandeman K; Kenttämies A; Nordling S; Mills IG; Tang J; Mirtti T; Rannikko A
Int J Cancer; 2024 Mar; 154(5):926-939. PubMed ID: 37767987
[TBL] [Abstract][Full Text] [Related]
2. Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
Lehto TK; Stürenberg C; Malén A; Erickson AM; Koistinen H; Mills IG; Rannikko A; Mirtti T
Prostate; 2021 May; 81(7):368-376. PubMed ID: 33734461
[TBL] [Abstract][Full Text] [Related]
3. Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy.
Eineluoto JT; Sandeman K; Pohjonen J; Sopyllo K; Nordling S; Stürenberg C; Malén A; Kilpeläinen TP; Santti H; Petas A; Matikainen M; Pellinen T; Järvinen P; Kenttämies A; Rannikko A; Mirtti T
Eur Urol Focus; 2021 Nov; 7(6):1316-1323. PubMed ID: 32620540
[TBL] [Abstract][Full Text] [Related]
4. Genes involved in prostate cancer progression determine MRI visibility.
Li P; You S; Nguyen C; Wang Y; Kim J; Sirohi D; Ziembiec A; Luthringer D; Lin SC; Daskivich T; Wu J; Freeman MR; Saouaf R; Li D; Kim HL
Theranostics; 2018; 8(7):1752-1765. PubMed ID: 29556354
[TBL] [Abstract][Full Text] [Related]
5. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
[TBL] [Abstract][Full Text] [Related]
6. Partial-gland Cryoablation Outcomes for Localized Prostate Cancer in Patients with Magnetic Resonance Imaging (MRI)-visible and MRI-invisible Lesions.
Zhu A; Gereta S; Zhang TR; Stangl-Kremser J; Mora RM; Margolis DJA; Hu JC
Eur Urol Open Sci; 2023 Jul; 53():38-45. PubMed ID: 37441341
[TBL] [Abstract][Full Text] [Related]
7. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings.
Purysko AS; Magi-Galluzzi C; Mian OY; Sittenfeld S; Davicioni E; du Plessis M; Buerki C; Bullen J; Li L; Madabhushi A; Stephenson A; Klein EA
Eur Radiol; 2019 Sep; 29(9):4861-4870. PubMed ID: 30847589
[TBL] [Abstract][Full Text] [Related]
8. Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer.
Pachynski RK; Kim EH; Miheecheva N; Kotlov N; Ramachandran A; Postovalova E; Galkin I; Svekolkin V; Lyu Y; Zou Q; Cao D; Gaut J; Ippolito JE; Bagaev A; Bruttan M; Gancharova O; Nomie K; Tsiper M; Andriole GL; Ataullakhanov R; Hsieh JJ
Clin Cancer Res; 2021 Jun; 27(12):3478-3490. PubMed ID: 33771855
[TBL] [Abstract][Full Text] [Related]
9. Prospective analysis of clinically significant prostate cancer detection with [
Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
[TBL] [Abstract][Full Text] [Related]
10. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
11. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
Williams C; Ahdoot M; Daneshvar MA; Hague C; Wilbur AR; Gomella PT; Shih J; Khondakar N; Yerram N; Mehralivand S; Gurram S; Siddiqui M; Pinsky P; Parnes H; Merino M; Wood B; Turkbey B; Pinto PA
J Urol; 2022 Jan; 207(1):95-107. PubMed ID: 34433302
[TBL] [Abstract][Full Text] [Related]
12. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
13. Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.
Schmid FA; Lieger L; Saba K; Sigg S; Lehner F; Waisbrod S; Müller A; Sulser T; Eberli D; Mortezavi A
Prostate; 2023 Jan; 83(1):56-63. PubMed ID: 36073730
[TBL] [Abstract][Full Text] [Related]
14. Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer.
Salami SS; Kaplan JB; Nallandhighal S; Takhar M; Tosoian JJ; Lee M; Yoon J; Hovelson DH; Plouffe KR; Kaffenberger SD; Schaeffer EM; Karnes RJ; Lotan TL; Morgan TM; George AK; Montgomery JS; Davenport MS; You S; Tomlins SA; Curci NE; Kim HL; Spratt DE; Udager AM; Palapattu GS
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914029
[TBL] [Abstract][Full Text] [Related]
15. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
16. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
19. Post Prostatectomy Pathologic Findings of Patients With Clinically Significant Prostate Cancer and no Significant PI-RADS Lesions on Preoperative Magnetic Resonance Imaging.
Alanee S; Deebajah M; Taneja K; Cole D; Pantelic M; Peabody J; Williamson SR; Gupta N; Dabaja A; Menon M
Urology; 2020 Dec; 146():183-188. PubMed ID: 32946907
[TBL] [Abstract][Full Text] [Related]
20. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
